Adaptimmune
Acquired by WorldMeds / NASDAQ: ADAP
Develops engineered T-cell therapies (TCR T-cells) to treat solid tumor and hematological cancers.
Develops engineered T-cell therapies (TCR T-cells) to treat solid tumor and hematological cancers.
Sector
Life SciencesCategory
TherapeuticsStatus
AcquiredLocation
Oxford, UKInitial Investment
2014Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Adaptimmune was acquired by WorldMeds in 2025.